Nuveen Asset Management LLC Sells 1,395,503 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Nuveen Asset Management LLC reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 29.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,419,046 shares of the biotechnology company's stock after selling 1,395,503 shares during the period. Nuveen Asset Management LLC owned approximately 1.65% of BioCryst Pharmaceuticals worth $25,711,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Venturi Wealth Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $46,000. R Squared Ltd acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $48,000. KBC Group NV boosted its position in BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after acquiring an additional 4,537 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $80,000. Finally, Syon Capital LLC bought a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth $99,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. JMP Securities reiterated a "market outperform" rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Royal Bank of Canada reissued an "outperform" rating and set a $13.00 target price (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Cantor Fitzgerald began coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price objective on the stock. Finally, Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $16.56.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX traded down $0.08 during trading on Wednesday, hitting $10.72. 642,101 shares of the company traded hands, compared to its average volume of 4,021,544. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $5.92 and a fifty-two week high of $11.11. The business's fifty day moving average is $8.50 and its 200 day moving average is $8.09. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -17.57 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. The company's quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the business earned $0.28 earnings per share. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.